Abdallah Abou Hajal, Lana Bustanji, Richard A Bryce, Mohammad A Ghattas
{"title":"An introduction to GitHub and its significance for AI-driven drug discovery.","authors":"Abdallah Abou Hajal, Lana Bustanji, Richard A Bryce, Mohammad A Ghattas","doi":"10.1080/17460441.2026.2641511","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>GitHub has become essential to AI-driven drug discovery by facilitating code sharing, collaboration, and reproducible workflows. As more tools for screening, modeling, and data-driven decision-making are hosted on GitHub, researchers need clear, rigorous methods to identify, evaluate, and reuse repositories in a scientifically robust manner.</p><p><strong>Areas covered: </strong>In this report, the authors summarize GitHub concepts most relevant to research practice (e.g. repositories, documentation, licensing, releases, testing, and archiving) and propose a practical framework for navigating drug-discovery repositories. The report incorporates a Scopus trend analysis from 2013 to 2024 using a GitHub-focused search with drug discovery keywords, as well as keyword-based counts of GitHub repositories in selected categories to show topic density.</p><p><strong>Expert opinion: </strong>GitHub repositories should be recognized as peer-assessable research outputs in AI-driven drug discovery rather than as supplementary material. At a minimum, this means clear documentation of intended use and limitations, a pinned environment or container for reproducibility, an explicit license, and automated testing via continuous integration. In addition, enhanced validation and governance are necessary to bridge exploratory research code with translational and industrial reliability expectations.</p>","PeriodicalId":12267,"journal":{"name":"Expert Opinion on Drug Discovery","volume":" ","pages":"387-392"},"PeriodicalIF":7.3000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17460441.2026.2641511","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: GitHub has become essential to AI-driven drug discovery by facilitating code sharing, collaboration, and reproducible workflows. As more tools for screening, modeling, and data-driven decision-making are hosted on GitHub, researchers need clear, rigorous methods to identify, evaluate, and reuse repositories in a scientifically robust manner.
Areas covered: In this report, the authors summarize GitHub concepts most relevant to research practice (e.g. repositories, documentation, licensing, releases, testing, and archiving) and propose a practical framework for navigating drug-discovery repositories. The report incorporates a Scopus trend analysis from 2013 to 2024 using a GitHub-focused search with drug discovery keywords, as well as keyword-based counts of GitHub repositories in selected categories to show topic density.
Expert opinion: GitHub repositories should be recognized as peer-assessable research outputs in AI-driven drug discovery rather than as supplementary material. At a minimum, this means clear documentation of intended use and limitations, a pinned environment or container for reproducibility, an explicit license, and automated testing via continuous integration. In addition, enhanced validation and governance are necessary to bridge exploratory research code with translational and industrial reliability expectations.
期刊介绍:
Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development.
The Editors welcome:
Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology
Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug
The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.